No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In BCG-Naive Patients With High-Risk Non-Muscle-Invasive Bladder Cancer By Ogkologos - November 17, 2025 260 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ALBAN (GETUG-AFU 37) study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR How you can do your part in the AI transformation of... October 7, 2025 Opioid Use Drops Among Cancer Patients at End of Life August 20, 2021 What Is Mindfulness and How Can It Help People With Cancer? July 5, 2022 Neoadjuvant Atezolizumab Plus Chemotherapy Is Safe and Has Promising Activity in... January 11, 2024 Load more HOT NEWS Adjuvant Chemotherapy Customisation Based on ERCC1 and TS mRNA Levels Does... Geriatric Assessment Intervention Reduces Patient-Reported Symptomatic Toxicities in Older Patients with... EMA Recommends Granting a Marketing Authorisation for Tebentafusp Osimertinib Improves Survival in Advanced Lung Cancer with EGFR Mutations
